Pedro Segura-Saldaña
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pedro Segura-Saldaña has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Diego Chambergo-Michilot
Universidad Científica del Sur, Lima, Perú
4 shared publications - Cristian Aguilar
Laboratorio de Patologia, Instituto Nacional Cardiovascular, Lima, Peru
3 shared publications - Mayita Alvarez-Vargas
Laboratorio de Ingeniería Biomédica, Departamento de Ingeniería, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia , 430 Honorio Delagado Avenue, San Martin de Porres, Lima 15102, Perú
3 shared publications - Brady Ernesto Beltran
Servicio de Oncología Médica, Hospital Edgardo Rebagliati Martins, Instituto de Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú
2 shared publications - Marcos Pariona
Departamento de Cardiología, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru
2 shared publications Tomas Carbajal
Department of Pathology Edgardo Rebagliati Martins National Hospital Lima Peru
2 shared publications
Latest Publications
- Open Access
- 22 August 2025
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 19
Impact of anemia on the association between red cell distribution width and 1-year mortality in acute heart failure patients
Background: Different accessible and low-cost biomarkers have been investigated to stratify patients with acute heart failure (AHF). One of them is the red cell distribution width (RDW), which proved to be a greater prognostic marker of mortality than other conventional markers. Objective: Therefore, the objective of our study is to determine whether the anemic status modifies the magnitude of association between high RDW and 1-year mortality in patients with AHF. Design: Observational, analytical, retrospective cohort study. Methods: We included participants ⩾18 years old hospitalized with a diagnosis of AHF. As an association measure, a crude and adjusted generalized linear model of the Poisson family calculated the risk ratio (RR) with a 95% confidence interval (95% CI). Results: In all, 709 participants with an average age of 73.48 years were included. At 1 year, the risk of dying was three times higher with high RDW (RR = 3.05, 95% CI: 1.39–6.66; p < 0.01). In anemic participants, the risk of dying at 1 year is two times greater with high RDW (RR = 2.18, 95% CI: 0.91–5.22; p = 0.07), while in non-anemic participants, the risk of dying increased almost seven times (RR = 6.95, 95% CI: 1.65–29.23; p < 0.01). Conclusion: High RDW is a risk factor for mortality at 1 year in patients with AHF. A greater magnitude of association was found in non-anemic patients.
- 22 August 2025
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 19
Open AccessImpact of anemia on the association between red cell distribution width and 1-year mortality in acute heart failure patients
Background: Different accessible and low-cost biomarkers have been investigated to stratify patients with acute heart failure (AHF). One of them is the red cell distribution width (RDW), which proved to be a greater prognostic marker of mortality than other conventional markers. Objective: Therefore, the objective of our study is to determine whether the anemic status modifies the magnitude of association between high RDW and 1-year mortality in patients with AHF. Design: Observational, analytical, retrospective cohort study. Methods: We included participants ⩾18 years old hospitalized with a diagnosis of AHF. As an association measure, a crude and adjusted generalized linear model of the Poisson family calculated the risk ratio (RR) with a 95% confidence interval (95% CI). Results: In all, 709 participants with an average age of 73.48 years were included. At 1 year, the risk of dying was three times higher with high RDW (RR = 3.05, 95% CI: 1.39–6.66; p < 0.01). In anemic participants, the risk of dying at 1 year is two times greater with high RDW (RR = 2.18, 95% CI: 0.91–5.22; p = 0.07), while in non-anemic participants, the risk of dying increased almost seven times (RR = 6.95, 95% CI: 1.65–29.23; p < 0.01). Conclusion: High RDW is a risk factor for mortality at 1 year in patients with AHF. A greater magnitude of association was found in non-anemic patients.
- Open Access
- 27 June 2024
- Published by Cuerpo Médico del Hospital Nacional Edgardo Rebagliati Martins in Revista Médica Rebagliati
- Vol. 4 (1) , 24-30
Factores asociados a síndrome coronario agudo en pacientes hospitalizados por COVID-19
Objective: To evaluate the factors associated with acute coronary syndrome (ACS) in patients hospitalized for COVID-19 at the Hospital Nacional Edgardo Rebagliati Martins (Lima, Peru). Materials and methods: A case-control study was conducted, recruiting two groups of patients based on the diagnosis of ACS during their hospitalization for COVID-19 between March 2020 and March 2021 (60 cases and 120 controls). Sociodemographic and clinical factors and data related to the diagnosis and hospitalization for COVID-19 were measured. Associations and thestrength of association (odds ratio, OR) were assessed using nonparametric bivariate analyzes and logistic regression. Results: In the bivariate analysis, it was observed that a history of arterial hypertension, heart failure, coronary disease, cancer, and previous acute coronary syndrome were found to be associated with presenting SICA (systemic inflammatory response syndromein children and adolescents). Likewise, during hospitalization, it was observed that cough,headache, systolic and diastolic blood pressure, sensory disorder, affected lobes, troponins, C-reactive protein, neutrophils, lymphocytes, and creatinine were associated with the event. In the multivariate analysis, only the aforementioned pathological antecedents were maintained. Conclusion: Although hospitalization for COVID-19 could be related to a higher frequency of SICA, the factors observed during hospitalization for COVID-19 would not significantly affect the occurrence of SICA.
- 27 June 2024
- Published by Cuerpo Médico del Hospital Nacional Edgardo Rebagliati Martins in Revista Médica Rebagliati
- Vol. 4 (1) , 24-30
Open AccessFactores asociados a síndrome coronario agudo en pacientes hospitalizados por COVID-19
Objective: To evaluate the factors associated with acute coronary syndrome (ACS) in patients hospitalized for COVID-19 at the Hospital Nacional Edgardo Rebagliati Martins (Lima, Peru). Materials and methods: A case-control study was conducted, recruiting two groups of patients based on the diagnosis of ACS during their hospitalization for COVID-19 between March 2020 and March 2021 (60 cases and 120 controls). Sociodemographic and clinical factors and data related to the diagnosis and hospitalization for COVID-19 were measured. Associations and thestrength of association (odds ratio, OR) were assessed using nonparametric bivariate analyzes and logistic regression. Results: In the bivariate analysis, it was observed that a history of arterial hypertension, heart failure, coronary disease, cancer, and previous acute coronary syndrome were found to be associated with presenting SICA (systemic inflammatory response syndromein children and adolescents). Likewise, during hospitalization, it was observed that cough,headache, systolic and diastolic blood pressure, sensory disorder, affected lobes, troponins, C-reactive protein, neutrophils, lymphocytes, and creatinine were associated with the event. In the multivariate analysis, only the aforementioned pathological antecedents were maintained. Conclusion: Although hospitalization for COVID-19 could be related to a higher frequency of SICA, the factors observed during hospitalization for COVID-19 would not significantly affect the occurrence of SICA.
- Open Access
- 12 May 2023
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 30 (3) , 265-279
Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis
Introduction COVID-19 related mortality is about 2%, and it increases with comorbidities, like hypertension. Regarding management, there is debatable evidence about the benefits of continuation vs. discontinuation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEI/ARB). Aim We performed a systematic review to assess the effects and safety of in-hospital discontinuation compared to continuation of ACEI/ARB in COVID-19 patients. Methods We systematically searched on PubMed, Scopus, and EMBASE from inception to June 19, 2021. We included observational studies and trials that compared the effects and safety of continuing ACEI/ARB compared to discontinuing it in COVID-19 patients. Effects sizes for dichotomous variables were expressed as risk ratios (RR) and 95% confidence intervals. For continuous variables, effects were expressed as mean difference (MD). We used random effect models with the inverse variance method. We assessed certainty of evidence using the GRADE approach. Results We included three open-label randomized controlled trials and five cohort studies. We found that the continuation group had lower risk of death compared with the discontinuation group only in the cohort group (RR: 0.46, 95% CI: 0.24–0.90), but not in the RCT group (RR: 1.22, 95% CI: 0.75–2.00). The ICU admission rate was significantly lower in the continuation group (RR: 0.46, 95% CI: 0.31–0.68) in the cohort group, but not in RCT group (RR: 1.03, 95% CI: 0.67–1.59). We did not find significant differences between groups regarding hospitalization length, hypotension, AKI needing renal replacement therapy, mechanical ventilation, new or worsening heart failure, myocarditis, renal replacement therapy, arrhythmias, thromboembolic events and SOFA AUC. The GRADE approach revealed that the certainty ranged from moderate to high level. Conclusions There is no significant difference in mortality and other outcomes between continuation and discontinuation groups.
- 12 May 2023
- Published by Springer Nature in High Blood Pressure & Cardiovascular Prevention
- Vol. 30 (3) , 265-279
Open AccessDiscontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis
Introduction COVID-19 related mortality is about 2%, and it increases with comorbidities, like hypertension. Regarding management, there is debatable evidence about the benefits of continuation vs. discontinuation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEI/ARB). Aim We performed a systematic review to assess the effects and safety of in-hospital discontinuation compared to continuation of ACEI/ARB in COVID-19 patients. Methods We systematically searched on PubMed, Scopus, and EMBASE from inception to June 19, 2021. We included observational studies and trials that compared the effects and safety of continuing ACEI/ARB compared to discontinuing it in COVID-19 patients. Effects sizes for dichotomous variables were expressed as risk ratios (RR) and 95% confidence intervals. For continuous variables, effects were expressed as mean difference (MD). We used random effect models with the inverse variance method. We assessed certainty of evidence using the GRADE approach. Results We included three open-label randomized controlled trials and five cohort studies. We found that the continuation group had lower risk of death compared with the discontinuation group only in the cohort group (RR: 0.46, 95% CI: 0.24–0.90), but not in the RCT group (RR: 1.22, 95% CI: 0.75–2.00). The ICU admission rate was significantly lower in the continuation group (RR: 0.46, 95% CI: 0.31–0.68) in the cohort group, but not in RCT group (RR: 1.03, 95% CI: 0.67–1.59). We did not find significant differences between groups regarding hospitalization length, hypotension, AKI needing renal replacement therapy, mechanical ventilation, new or worsening heart failure, myocarditis, renal replacement therapy, arrhythmias, thromboembolic events and SOFA AUC. The GRADE approach revealed that the certainty ranged from moderate to high level. Conclusions There is no significant difference in mortality and other outcomes between continuation and discontinuation groups.
- Open Access
- 6 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0273949
Trends and geographical variation in mortality from coronary disease in Peru
Background: Coronary disease (CD) is the main cause of mortality worldwide. Data about trends and geographical variation in CD mortality is available in some American countries. This information varies among countries since CD risk factors frequencies vary.Objective: To describe the trend and geographical variation of coronary disease (CD) mortality in Peru, 2005–2017.Methods: Analysis of secondary data of the Peruvian Ministry of Health’s registry of deaths. We analyzed CD mortality. We described the absolute and relative frequency of deaths and age-standardized mortality rate (ASMR) by natural regions, departments, age, sex, and year. We also described the change of ASMR between two periods (2005–2010 vs. 2011–2017).Results: There were 64,721 CD deaths between 2005 and 2017 (4.12% among all deaths). The absolute frequency of CD deaths was 5,665 and 6,565 in 2005 and 2017, respectively. CD mortality was more frequent in men and older adults. The ASMR varied among natural regions, being higher in the Coast (19.61 per 100,000 inhabitants). The change between the two periods revealed that almost all departments reduced their ASMRs, except for Callao, Lambayeque, and Madre de Dios.Conclusion: CD mortality has increased in Peru. Mortality was higher in men and older adults, and it varied among departments. More political efforts are needed to reduce these trends.
- 6 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0273949
Open AccessTrends and geographical variation in mortality from coronary disease in Peru
Background: Coronary disease (CD) is the main cause of mortality worldwide. Data about trends and geographical variation in CD mortality is available in some American countries. This information varies among countries since CD risk factors frequencies vary.Objective: To describe the trend and geographical variation of coronary disease (CD) mortality in Peru, 2005–2017.Methods: Analysis of secondary data of the Peruvian Ministry of Health’s registry of deaths. We analyzed CD mortality. We described the absolute and relative frequency of deaths and age-standardized mortality rate (ASMR) by natural regions, departments, age, sex, and year. We also described the change of ASMR between two periods (2005–2010 vs. 2011–2017).Results: There were 64,721 CD deaths between 2005 and 2017 (4.12% among all deaths). The absolute frequency of CD deaths was 5,665 and 6,565 in 2005 and 2017, respectively. CD mortality was more frequent in men and older adults. The ASMR varied among natural regions, being higher in the Coast (19.61 per 100,000 inhabitants). The change between the two periods revealed that almost all departments reduced their ASMRs, except for Callao, Lambayeque, and Madre de Dios.Conclusion: CD mortality has increased in Peru. Mortality was higher in men and older adults, and it varied among departments. More political efforts are needed to reduce these trends.
- Open Access
- 5 September 2022
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 93 (2)
Red blood cell distribution width to predict mortality in heart transplant recipients: a systematic review
Red blood cell distribution width (RDW) has been shown to have prognostic value in a number of different clinical settings, such as cardiovascular disease, including heart failure. However, its prognostic value in heart transplant (HT) recipients remains unknown. The aim of this systematic review is to determine the prognostic value of pre-transplant RDW for mortality in HT recipients. There is a pre-published protocol of this review. The terms "Heart transplant", "Red cell distribution width" and their synonyms were used in the search strategy. PubMed/Medline, Embase, Scopus, Web of Science and LILACS were searched until May 17th, 2022, without date or language restrictions. Two authors independently carried out the selection, first by title and abstract, second by full-text revision. Discrepancies were discussed and resolved with three other authors. Quality of individual studies was assessed with Newcastle Ottawa Scale (NOS) for cohorts. After removing the duplicates, 3885 articles were identified. Four articles were included in the qualitative synthesis. Three studies were classified as “good quality”: whereas one as “poor quality” according to NOS scale. All the included articles evaluated long-term mortality and one study also evaluated short-term mortality. In this one, a correlation between higher RDW values and short-term mortality was reported. Meanwhile, in all the studies, a high pre-HT RDW was a marker of long-term mortality following cardiac transplantation. Our review shows that an elevated on-admission RDW is associated with long-term mortality in heart transplantation recipients.
- 5 September 2022
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 93 (2)
Open AccessRed blood cell distribution width to predict mortality in heart transplant recipients: a systematic review
Red blood cell distribution width (RDW) has been shown to have prognostic value in a number of different clinical settings, such as cardiovascular disease, including heart failure. However, its prognostic value in heart transplant (HT) recipients remains unknown. The aim of this systematic review is to determine the prognostic value of pre-transplant RDW for mortality in HT recipients. There is a pre-published protocol of this review. The terms "Heart transplant", "Red cell distribution width" and their synonyms were used in the search strategy. PubMed/Medline, Embase, Scopus, Web of Science and LILACS were searched until May 17th, 2022, without date or language restrictions. Two authors independently carried out the selection, first by title and abstract, second by full-text revision. Discrepancies were discussed and resolved with three other authors. Quality of individual studies was assessed with Newcastle Ottawa Scale (NOS) for cohorts. After removing the duplicates, 3885 articles were identified. Four articles were included in the qualitative synthesis. Three studies were classified as “good quality”: whereas one as “poor quality” according to NOS scale. All the included articles evaluated long-term mortality and one study also evaluated short-term mortality. In this one, a correlation between higher RDW values and short-term mortality was reported. Meanwhile, in all the studies, a high pre-HT RDW was a marker of long-term mortality following cardiac transplantation. Our review shows that an elevated on-admission RDW is associated with long-term mortality in heart transplantation recipients.
- 31 May 2021
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 74 (3) , 228-232
When Frequent (Pandemic) Occurs in a Non-Frequent Disease: COVID-19 and Fabry Disease: Report of Two Cases
Fabry disease (FD), like COVID-19, can affect multiple organs, including the lungs. Patients with FD would be expected to develop severe forms of COVID-19, not only because of lung involvement but also because of renal involvement and other comorbidities. We present two cases of patients with Fabry disease who had an infection by COVID-19. In the two cases presented, they presented mild forms of COVID-19. Although the role of the X chromosome mutation in FD on the development of severe forms of COVID-19 is unknown; in the cases presented, it is suggested that it may play a protective role in the development of COVID-19. Two cases are presented; it is suggested that FD would not be a risk factor for severe COVID-19.
- 31 May 2021
- Published by Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis in Japanese Journal of Infectious Diseases
- Vol. 74 (3) , 228-232
When Frequent (Pandemic) Occurs in a Non-Frequent Disease: COVID-19 and Fabry Disease: Report of Two Cases
Fabry disease (FD), like COVID-19, can affect multiple organs, including the lungs. Patients with FD would be expected to develop severe forms of COVID-19, not only because of lung involvement but also because of renal involvement and other comorbidities. We present two cases of patients with Fabry disease who had an infection by COVID-19. In the two cases presented, they presented mild forms of COVID-19. Although the role of the X chromosome mutation in FD on the development of severe forms of COVID-19 is unknown; in the cases presented, it is suggested that it may play a protective role in the development of COVID-19. Two cases are presented; it is suggested that FD would not be a risk factor for severe COVID-19.
- Open Access
- 9 August 2020
- Published by Wiley in Neuropathology
- Vol. 41 (1) , 49-57
Cerebral embolization associated with parenchymal seeding of the left atrial myxoma: Potential role of interleukin‐6 and matrix metalloproteinases
Systemic embolization has been reported in up to 40% of patients with left atrial myxoma, half of them with cerebral involvement. However, development of intracerebral embolization associated with parenchymal seeding of the myxoma emboli is an extremely rare complication, with only 36 histologically diagnosed cases reported in the published literature. We describe a 69‐year‐old woman who arrived at the emergency service with hemiparesis associated with drug‐resistant epilepsy and a medical history of resection of a left atrial myxoma 10 months previously. Cranial computed tomography revealed multiple large lesions of heterogeneous density and cystic components in the occipital lobes and posterior fossa parenchyma. Histopathological analyses after stereotactic biopsy of the occipital lesion revealed infiltrative myxoma cells with benign histological findings and uniform expression of calretinin similar to that of the primary cardiac myxoma. Additional immunohistochemical studies confirmed brain parenchymal seeding of the myxoma cells with strong expression of interleukin‐6 (IL‐6) and focal expression of matrix metalloproteinases‐2 (MMP‐2). Here, we discuss the clinicopathological features of intracerebral embolization of left atrial myxomas associated with progressive parenchymal seeding of the tumor emboli and the potential pathogenic role of IL‐6 and MMPs.
- 9 August 2020
- Published by Wiley in Neuropathology
- Vol. 41 (1) , 49-57
Open AccessCerebral embolization associated with parenchymal seeding of the left atrial myxoma: Potential role of interleukin‐6 and matrix metalloproteinases
Systemic embolization has been reported in up to 40% of patients with left atrial myxoma, half of them with cerebral involvement. However, development of intracerebral embolization associated with parenchymal seeding of the myxoma emboli is an extremely rare complication, with only 36 histologically diagnosed cases reported in the published literature. We describe a 69‐year‐old woman who arrived at the emergency service with hemiparesis associated with drug‐resistant epilepsy and a medical history of resection of a left atrial myxoma 10 months previously. Cranial computed tomography revealed multiple large lesions of heterogeneous density and cystic components in the occipital lobes and posterior fossa parenchyma. Histopathological analyses after stereotactic biopsy of the occipital lesion revealed infiltrative myxoma cells with benign histological findings and uniform expression of calretinin similar to that of the primary cardiac myxoma. Additional immunohistochemical studies confirmed brain parenchymal seeding of the myxoma cells with strong expression of interleukin‐6 (IL‐6) and focal expression of matrix metalloproteinases‐2 (MMP‐2). Here, we discuss the clinicopathological features of intracerebral embolization of left atrial myxomas associated with progressive parenchymal seeding of the tumor emboli and the potential pathogenic role of IL‐6 and MMPs.
- Open Access
- 23 July 2020
- Published by Wiley in Journal of Arrhythmia
- Vol. 36 (5) , 845-848
Impact of COVID‐19 on pacemaker implant
Objectives The purpose of this article was to determine the change in the volume of pacemaker implantations with the COVID‐2019 pandemic and to assess the change in the number of pacemaker implants according to etiology during the pandemic. Background The establishment of a mandatory social isolation have generated a decrease in activities in cardiology units. Methods Descriptive, cross‐sectional study that used a database of a Peruvian Hospital. Time was divided into three categories: Before COVID period and COVID period including Previous to Social isolation (SI) and Social Isolation. The number of pacemaker implantations were compared per the same amount of time. Results A reduction in the pacemaker implant of 73% (95% CI: 33‐113; P < .001) was observed during the COVID‐19 pandemic period, and a reduction of 78% of patients with the diagnosis of complete or high‐grade atrioventricular block and a reduction in the de‐novo pacemaker implant was observed, regardless of the etiology. Conclusions Our results indicate a very significant reduction (73%) in de‐novo pacemaker implantation during the months of the COVID‐19 pandemic. The reduction in the number of de‐novo pacemaker occurred independent of the etiology.
- 23 July 2020
- Published by Wiley in Journal of Arrhythmia
- Vol. 36 (5) , 845-848
Open AccessImpact of COVID‐19 on pacemaker implant
Objectives The purpose of this article was to determine the change in the volume of pacemaker implantations with the COVID‐2019 pandemic and to assess the change in the number of pacemaker implants according to etiology during the pandemic. Background The establishment of a mandatory social isolation have generated a decrease in activities in cardiology units. Methods Descriptive, cross‐sectional study that used a database of a Peruvian Hospital. Time was divided into three categories: Before COVID period and COVID period including Previous to Social isolation (SI) and Social Isolation. The number of pacemaker implantations were compared per the same amount of time. Results A reduction in the pacemaker implant of 73% (95% CI: 33‐113; P < .001) was observed during the COVID‐19 pandemic period, and a reduction of 78% of patients with the diagnosis of complete or high‐grade atrioventricular block and a reduction in the de‐novo pacemaker implant was observed, regardless of the etiology. Conclusions Our results indicate a very significant reduction (73%) in de‐novo pacemaker implantation during the months of the COVID‐19 pandemic. The reduction in the number of de‐novo pacemaker occurred independent of the etiology.
- Open Access
- 4 September 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (17) , e008981
INCA (Peru) Study: Impact of Non‐Invasive Cardiac Magnetic Resonance Assessment in the Developing World
Background: Advanced cardiac imaging permits optimal targeting of cardiac treatment but needs to be faster, cheaper, and easier for global delivery. We aimed to pilot rapid cardiac magnetic resonance ( CMR ) with contrast in a developing nation, embedding it within clinical care along with training and mentoring. Methods and Results: A cross‐sectional study of CMR delivery and clinical impact assessment performed 2016–2017 in an upper middle‐income country. An International partnership (clinicians in Peru and collaborators from the United Kingdom, United States, Brazil, and Colombia) developed and tested a 15‐minute CMR protocol in the United Kingdom, for cardiac volumes, function and scar, and delivered it with reporting combined with training, education and mentoring in 2 centers in the capital city, Lima, Peru, 100 patients referred by local doctors from 6 centers. Management changes related to the CMR were reviewed at 12 months. One‐hundred scans were conducted in 98 patients with no complications. Final diagnoses were cardiomyopathy (hypertrophic, 26%; dilated, 22%; ischemic, 15%) and 12 other pathologies including tumors, congenital heart disease, iron overload, amyloidosis, genetic syndromes, vasculitis, thrombi, and valve disease. Scan cost was $150 USD, and the average scan duration was 18±7 minutes. Findings impacted management in 56% of patients, including previously unsuspected diagnoses in 19% and therapeutic management changes in 37%. Conclusions: Advanced cardiac diagnostics, here CMR with contrast, is possible using existing infrastructure in the developing world in 18 minutes for $150, resulting in important changes in patient care.
- 4 September 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (17) , e008981
Open AccessINCA (Peru) Study: Impact of Non‐Invasive Cardiac Magnetic Resonance Assessment in the Developing World
Background: Advanced cardiac imaging permits optimal targeting of cardiac treatment but needs to be faster, cheaper, and easier for global delivery. We aimed to pilot rapid cardiac magnetic resonance ( CMR ) with contrast in a developing nation, embedding it within clinical care along with training and mentoring. Methods and Results: A cross‐sectional study of CMR delivery and clinical impact assessment performed 2016–2017 in an upper middle‐income country. An International partnership (clinicians in Peru and collaborators from the United Kingdom, United States, Brazil, and Colombia) developed and tested a 15‐minute CMR protocol in the United Kingdom, for cardiac volumes, function and scar, and delivered it with reporting combined with training, education and mentoring in 2 centers in the capital city, Lima, Peru, 100 patients referred by local doctors from 6 centers. Management changes related to the CMR were reviewed at 12 months. One‐hundred scans were conducted in 98 patients with no complications. Final diagnoses were cardiomyopathy (hypertrophic, 26%; dilated, 22%; ischemic, 15%) and 12 other pathologies including tumors, congenital heart disease, iron overload, amyloidosis, genetic syndromes, vasculitis, thrombi, and valve disease. Scan cost was $150 USD, and the average scan duration was 18±7 minutes. Findings impacted management in 56% of patients, including previously unsuspected diagnoses in 19% and therapeutic management changes in 37%. Conclusions: Advanced cardiac diagnostics, here CMR with contrast, is possible using existing infrastructure in the developing world in 18 minutes for $150, resulting in important changes in patient care.